CRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose levels Phase 2 proof-of-concept trial in cardiovascular risk planned to ...

The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an ...

BioAge Labs said its investigational pill for cardiovascular risk prevention significantly reduced inflammation in an early ...

BioAge Labs Inc BIOA shares are up on Tuesday after the company reported positive Phase 1 data for BGE-102, an oral NLRP3 ...

Shares of BioAge Labs were higher after the company shared positive data for a trial of its drug as a treatment for inflammation. The stock gained 9% to $20.49 in pre-market trading Tuesday. Through ...

(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong ...

Interest in metabolic medicines is riding high, led by the popular class of weight management drugs known as GLP-1 agonists. BioAge Labs aims to help those medications work better with a lead drug ...

Sept 26 (Reuters) - Shares of BioAge Labs (BIOA.O), opens new tab opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the ...

BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human ...

BioAge Labs (NASDAQ: BIOA) is a small drugmaker whose shares have caught fire this year. The company has made clinical progress in the hottest therapeutic area in the industry right now: Weight ...

The mean of analysts' price targets for BioAge Labs, Inc. (BIOA) points to an 183.7% upside in the stock. While this highly ...

BioAge now offering 10.5 mln shares, vs 7.5 mln earlier Sofinnova expected to invest up to $1.4 mln in IPO Investment firm expected to buy shares worth $10.6 mln in private placement Sept 25 (Reuters) ...